Quasiparticle band structure

Many body effects influence the energy-versus-momentum relation that is measured in angle resolved photoemission experiments and the quasiparticle band structure may be significantly different from what is deduced within the independent particle model. In the case of cobalt many body effects are even more drastic than an energy renormalization giving rise to a quenching of quasiparticle peaks. Augmenting ab-initio band structure with many-body e-e interactions we have obtained spin- and k-dependent self-energies, hole spectral functions and quasiparticle energies to be compared with photoemission spectra; our results show that e-e correlations are responsible for strong spin-dependent energy renormalizations

MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?

Recent advances in the field of RNA research have provided compelling evidence implicating microRNA (miRNA) and long non-coding RNA molecules in many diverse and substantial biological processes, including transcriptional and post-transcriptional regulation of gene expression, genomic imprinting, and modulation of protein activity. Thus, studies of non-coding RNA (ncRNA) may contribute to the discovery of possible biomarkers in human cancers. Considering that the response to chemotherapy can differ amongst individuals, researchers have begun to isolate and identify the genes responsible. Identification of targets of this ncRNA associated with cancer can suggest that networks of these linked to oncogenes or tumor suppressors play pivotal roles in cancer development. Moreover, these ncRNA are attractive drug targets since they may be differentially expressed in malignant versus normal cells and regulate expression of critical proteins in the cell. This review focuses on ncRNAs that are differently expressed in malignant tissue, and discusses some of challenges derived from their use as potential biomarkers of tumor properties

TECHNICAL AND ECONOMICAL FEASIBILITY OF SEABASS FRY PRODUCTION ACCORDING TO ORGANIC TECHNIQUES

Over the past few years, consumers have been increasing their awareness about environmental, health and safety concerns and they have been gradually changing their habits in favor of organic food. In aquaculture sector, the most recent legislative framework regarding the organic production in Europe is the Commission Regulation (EC) 710/2009, where chapter for aquaculture animals include requirement for animal welfare conditions in husbandry and maximum stocking densities. In Italy, only ten farms are involved in the supply of certified organic fish and only some pilot projects were carried out for organic farming of different species. Therefore, the purpose of this research was to define or verify the principal standards for organic seabass farming, evaluating technical feasibility and production costs, comparing them with conventional production. This study contains the first considerations about organic production and its relative costs for sea bass fry, one of the most reared species of the country. Conversion to organic production naturally involves additional costs concerning the conversion process itself, the production of a new type of product and the lower output. In fact, results have shown that certification and feed costs represented the most significant difference between conventional and organic production. Finally, the current market situation is characterized by a low demand, an inadequately product differentiation from conventional (domestic or foreign) ones, a legislation still in progress, an unstructured and lower offer of organic products which does not allow to consider organic aquaculture as an activity that today can assure adequate profitability for the most part of Italian aquaculture firms

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Breast cancer; Estrogen receptorCáncer de mama; Receptor de estrógenosCàncer de mama; Receptor d'estrògensPurpose: Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor–positive (ER+) breast cancer. We present the primary analysis results of the phase Ia/b GO39932 study (NCT03332797). Patients and Methods: Patients with ER+, HER2-negative locally advanced/metastatic breast cancer previously treated with endocrine therapy received single-agent giredestrant (10, 30, 90, or 250 mg), or giredestrant (100 mg) ± palbociclib 125 mg ± luteinizing hormone-releasing hormone (LHRH) agonist. Detailed cardiovascular assessment was conducted with giredestrant 100 mg. Endpoints included safety (primary), pharmacokinetics, pharmacodynamics, and efficacy. Results: As of January 28, 2021, with 175 patients enrolled, no dose-limiting toxicity was observed, and the MTD was not reached. Adverse events (AE) related to giredestrant occurred in 64.9% and 59.4% of patients in the single-agent ± LHRH agonist and giredestrant + palbociclib ± LHRH agonist cohorts, respectively (giredestrant-only–related grade 3/4 AEs were reported in 4.5% of patients across the single-agent cohorts and 3.1% of those with giredestrant + palbociclib). Dose-dependent asymptomatic bradycardia was observed, but no clinically significant changes in cardiac-related outcomes: heart rate, blood pressure, or exercise duration. Clinical benefit was observed in all cohorts (48.6% of patients in the single-agent cohort and 81.3% in the giredestrant + palbociclib ± LHRH agonist cohort), with no clear dose relationship, including in patients with ESR1-mutated tumors. Conclusions: Giredestrant was well tolerated and clinically active in patients who progressed on prior endocrine therapy. Results warrant further evaluation of giredestrant in randomized trials in early- and late-stage ER+ breast cancer.This study was funded by Genentech, Inc., South San Francisco, California. K.L. Jhaveri of Memorial Sloan Kettering Cancer Center was also funded by NIH grant P30 CA008748. We thank all the patients who participated in the study, and their families, the investigators, clinicians, and research staff at the 23 centers in five countries. S. Loi is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. Support for third-party writing assistance for this article, furnished by Laura Pérez-Pachón, on behalf of Health Interactions in London, UK, was provided by F. Hoffmann-La Roche Ltd. This work was supported by Genentech, Inc., South San Francisco, California (no grant number applicable). The funder was involved in the study design, provision of study drugs, protocol development, regulatory and ethics approvals, safety monitoring, data collection, data analysis, data interpretation, and writing of the report, in collaboration with the study authors. All authors had full access to all study data and had final responsibility for the decision to submit for publication. The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734

A self-calibrating IoT portable electrochemical immunosensor for serum human epididymis protein 4 as a tumor biomarker for ovarian cancer

Nowadays analytical techniques are moving towards the development of smart biosensing strategies for point-of-care accurate screening of disease biomarkers, such as human epididymis protein 4 (HE4), a recently discovered serum markers for early ovarian cancer diagnosis. In this context, the present work represents the first implementation of a competitive enzyme-labelled magneto-immunoassay exploiting a homemade IoT Wi-Fi cloud-based portable potentiostat for differential pulse voltammetry readout. The electrochemical device was specifically designed capable of autonomous calibration and data processing, switching between calibration and measurement modes: in particular, firstly a baseline estimation algorithm is applied for correct peak computation, then calibration function is built by interpolating data with a four-parameter logistic function. The calibration function parameters are stored on the cloud for inverse prediction to determine the concentration of unknown samples. Interpolation function calibration and concentration evaluation are performed directly on-board, reducing the power consumption. The analytical device was validated in human serum, demonstrating good sensing performance for analysis of HE4 with detection and quantitation limits in human serum of 3.5 and 29.2 pM, respectively, reaching the sensitivity required for diagnostic purposes, with high potential for applications as portable and smart diagnostic tool for point-of-care testing

A Wi-Fi cloud-based portable potentiostat for electrochemical biosensors

The measurement of the analyte concentration in electrochemical biosensors traditionally requires costly laboratory equipment to obtain accurate results. Innovative portable solutions have recently been proposed, but usually, they lean on personal computers (PCs) or smartphones for data elaboration and they exhibit poor resolution or portability and proprietary software. This paper presents a low-cost portable system, assembling an ad hoc -designed analog front end (AFE) and a development board equipped with a system on chip integrating a microcontroller and a Wi-Fi network processor. The wireless module enables the transmission of measurements directly to a cloud service for sharing device outcome with users (physicians, caregivers, and so on). In doing so, the system does not require neither the customized software nor other devices involved in data acquisition. Furthermore, when any Internet connection is lost, the data are stored on board for subsequent transmission when a Wi-Fi connection is available. The noise output voltage spectrum has been characterized. Since the designed device is intended to be battery-powered to enhance portability, investigations about battery lifetime were carried out. Finally, data acquired with a conventional benchtop Autolab PGSTAT-204 electrochemical workstation are compared with the outcome of our developed device to validate the effectiveness of our proposal. To this end, we selected ferri/ferrocyanide as redox probe, obtaining the calibration curves for both the platforms. The final outcomes are shown to be feasible, accurate, and repeatable

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Ewing Sarcoma; LurbinectedinSarcoma de Ewing; LurbinectedinaSarcoma d'Ewing; LurbinectedinaPurpose: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. On the basis of this rationale, lurbinectedin was evaluated in patients with relapsed Ewing sarcoma. Patients and Methods: This open-label, single-arm, Basket phase II trial included a cohort of 28 treated adult patients with confirmed Ewing sarcoma, measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1, Eastern Cooperative Oncology Group performance status ≤2, adequate organ function, no central nervous system metastasis, and pretreated with ≤2 chemotherapy lines for metastatic/recurrent disease. Patients received lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks. Primary endpoint was overall response rate (ORR) as per RECIST v.1.1. Secondary endpoints included time-to-event parameters and safety profile. Results: ORR was 14.3% [95% confidence interval (CI), 4.0%–32.7%], with median duration of response of 4.2 months (95% CI, 2.9–5.5 months). Median progression-free survival was 2.7 months (95% CI, 1.4–4.3 months), clinical benefit rate was 39.3%, and disease control rate was 57.1%. With 39% censoring, median overall survival was 12.0 months (95% CI, 8.5–18.5 months). Most common grade 3/4 adverse events were neutropenia (57%), anemia, thrombocytopenia, and treatment-related febrile neutropenia (14% each). No deaths or discontinuations were due to toxicity. Conclusions: Lurbinectedin was active in the treatment of relapsed Ewing sarcoma and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for Ewing sarcoma, and is currently being evaluated in combination with irinotecan in advanced Ewing sarcoma in a phase Ib/II trial

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

Breast cancer; Lurbinectedin; Response rateCáncer de mama; Lurbinectedina; Tasa de respuestaCàncer de mama; Lurbinectedina; Taxa de respostaBackground Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient models and preliminary clinical activity in BRCA1/2 breast cancer. Patients and methods This phase II basket multitumor trial (NCT02454972) evaluated lurbinectedin 3.2 mg/m2 1-h intravenous infusion every 3 weeks in a cohort of 21 patients with pretreated germline BRCA1/2 breast cancer. Patients with any hormone receptor and human epidermal growth factor receptor 2 status were enrolled. The primary efficacy endpoint was overall response rate (ORR) according to RECIST v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. Results Confirmed partial response (PR) was observed in six patients [ORR = 28.6%; 95% confidence interval (CI) 11.3% to 52.2%] who had received a median of two prior advanced chemotherapy lines. Lurbinectedin was active in both BRCA mutations: four PRs in 11 patients (36.4%) with BRCA2 and two PRs in 10 patients (20.0%) with BRCA1. Median DoR was 8.6 months, median PFS was 4.1 months and median OS was 16.1 months. Stable disease (SD) was observed in 10 patients (47.6%), including 3 with unconfirmed response in a subsequent tumor assessment [ORR unconfirmed = 42.9% (95% CI 21.8% to 66.0%)]. Clinical benefit rate (PR + SD ≥ 4 months) was 76.2% (95% CI 52.8% to 91.8%). No objective response was observed among patients who had received prior poly (ADP-ribose) polymerase inhibitors. The most common treatment-related adverse events (AEs) were nausea (61.9%), fatigue (38.1%) and vomiting (23.8%). These AEs were mostly grade 1/2. The most common grade 3/4 toxicity was neutropenia (42.9%: grade 4, 23.8%: with no febrile neutropenia). Conclusions This phase II study met its primary endpoint and showed activity of lurbinectedin in germline BRCA1/2 breast cancer. Lurbinectedin showed a predictable and manageable safety profile. Considering the exploratory aim of this trial as well as previous results in other phase II studies, further development of lurbinectedin in this indication is warranted.This work was supported by PharmaMar S.A, including partial funding by grants from the Centro para el Desarrollo Tecnológico IndustrialCentro para el Desarrollo Tecnológico Industrial (CDTI) during the conduct of the study (grant number IDI-20150006). VS is supported by NIH [grant number R01CA242845]. MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas [grant number RP1100584], the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy [grant number 1U01 CA180964], NCATS [grant number UL1 TR000371] (Center for Clinical and Translational Sciences) and the MD Anderson Cancer Center Support [grant number P30 CA016672]

IoT and Biosensors: A Smart PortablePotentiostat With AdvancedCloud-Enabled Features

Recent advances in Internet-of-Things technology have opened the doors to new scenariosfor biosensor applications. Flexibility, portability, and remote control and access are of utmost importanceto move these devices to people’s homes or in a Point-of-Care context and rapidly share the results withusers and their physicians. In this paper, an innovative portable device for both quantitative and semi-quantitative electrochemical analysis is presented. This device can operate autonomously without the needof relying on other devices (e.g., PC, tablets, or smartphones) thanks to built-in Wi-Fi connectivity. Thedeveloped hardware is integrated into a cloud-based platform, exploiting the cloud computational powerto perform innovative algorithms for calibration (e.g., Machine Learning tools). Results and configurationscan be accessed through a web page without the installation of dedicated APPs or software. The electricalinput/output characteristic was measured with a dummy cell as a load, achieving excellent linearity.Furthermore, the device response to five different concentrations of potassium ferri/ferrocyanide redox probewas compared with a bench-top laboratory instrument. No difference in analytical sensitivity was found.Also, some examples of application-specific tests were set up to demonstrate the use in real-case scenarios.In addition, Support Vector Machine algorithm was applied to semi-quantitative analyses to classify theinput samples into four classes, achieving an average accuracy of 98.23%. Finally, COVID-19 related testsare presented and discussed (PDF) IoT and Biosensors: A Smart Portable Potentiostat With Advanced Cloud-Enabled Features. Available from: https://www.researchgate.net/publication/355214115_IoT_and_Biosensors_A_Smart_Portable_Potentiostat_With_Advanced_Cloud-Enabled_Features [accessed Oct 25 2021]

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

Lurbinectedin; Phase II; Pooled safetyLurbinectedina; Fase II; Seguretat conjuntaLurbinectedina; Fase II; Seguridad conjuntaBackground Lurbinectedin was approved by FDA and other health regulatory agencies for treating adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Safety profile at approved dose (3.2 mg/m2 every 3 weeks) was acceptable and manageable in 105 adult SCLC patients from a phase II basket trial. This study analyses safety data from several solid tumours treated at the lurbinectedin-approved dose. Methods Data were pooled from 554 patients: 335 from all nine tumour-specific cohorts of the phase II basket trial and 219 from a randomised phase III trial (CORAIL) in platinum-resistant ovarian cancer. Events and laboratory abnormalities were graded using NCI-CTCAE v.4. Results Most common tumours were ovarian (n = 219, 40%), SCLC (n = 105, 19%) and endometrial (n = 73, 13%). Transient haematological laboratory abnormalities were the most frequent grade 3 or more events: neutropenia (41%), leukopenia (30%), anaemia (17%) and thrombocytopenia (10%). Most common treatment-emergent non-haematological events (any grade) were transient transaminase increases (alanine aminotransferase [66%], aspartate aminotransferase [53%]), fatigue (63%), nausea (57%), constipation (32%), vomiting (30%) and decreased appetite (25%). Dose reductions were mostly due to haematological toxicities, but most patients (79%) remained on full lurbinectedin dose. Serious events mostly consisted of haematological disorders. Eighteen treatment discontinuations (3%) and seven deaths (1%) were due to treatment-related events. Conclusions This analysis confirms a manageable safety profile for lurbinectedin in patients with advanced solid tumours. Findings are consistent with those reported in patients with relapsed SCLC, Ewing sarcoma, germline BRCA1/2 metastatic breast cancer, neuroendocrine tumours and ovarian cancer.The trials were funded by Pharma Mar SA, including grants from the Centro para el Desarrollo Tecnológico Industrial (CDTI) during the conduct of the study